Navigation Links
Nephros Receives 510k Approval to Market Additional Ultrafiltration Products
Date:7/21/2011

please visit the company's website at www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to continue as a going concern; (ii) to obtain additional funding when needed or on favorable terms; (iii) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (iv) to have its technologies and products accepted in current or future target markets; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; or (vi) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros' filings with the SEC. Investors and security holders are encouraged to read these documents on the SEC's website at http://www.sec.gov/. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or other
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. Nephros Rights Offering Registration Statement Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ATLANTA , May 21, 2015  CryoLife, Inc. ... tissue processing company focused on cardiac and vascular surgery, ... a quarterly cash dividend for the second quarter 2015 ... quarterly cash dividend of $0.03 per share will be ... of record as of June 12, 2015.  The ex-dividend ...
(Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
(Date:5/21/2015)... , May 21, 2015 Northwest Biotherapeutics, ... company developing DCVax® personalized immune therapies for cancer, announced ... Technical Officer of the Company, will be making a ... on Emerging Approaches to Immunotherapy at 11:40 a.m. on May ... York City . Dr. Bosch,s ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3NW Bio To Present At New York Academy Of Sciences' Conference On Emerging Approaches To Immunotherapy 2NW Bio To Present At New York Academy Of Sciences' Conference On Emerging Approaches To Immunotherapy 3
... 2011 First results from a large-scale Phase III ... New England Journal of Medicine (NEJM) , show the ... significant protection against clinical and severe malaria with an ... today at the Malaria Forum hosted by the Bill ...
... 2011 Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee ... ("Epix") announced today that the S1P1 lead compounds, AMG ... 2011 in a sealed bid sale.  S1P1 agonists are ... MS is the second most common cause of ...
Cached Medicine Technology:First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 2First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 3First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 4First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 5First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 6First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 7First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months 8S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis 2
(Date:5/22/2015)... (PRWEB) May 22, 2015 In April ... In the past 9 years they have concentrated their ... United States and Canada. Because of this growth and ... established corporate offices in Denver, Colorado, Cleveland, Ohio, Houston, ... specializes in opening new dental offices, dental start ups, ...
(Date:5/22/2015)... A new program for the "In America" television series ... Therapy. , James Earl Jones will host the ... therapy and discusses how the exercises can decrease pain ... ailments and injuries. Physical therapists work with their ... daily activities such as house cleaning and shopping, work ...
(Date:5/22/2015)... Maine (PRWEB) May 22, 2015 ... single-use swabs for the medical, diagnostic, environmental, and ... entire line of products in the US. At ... their operations outside the US, Puritan remains committed ... products at their Guilford, Maine facility. , Since ...
(Date:5/22/2015)... May 22, 2015 Yisrayl Hawkins, Pastor and ... released a new letter calling on religious leaders to make ... which was published on his blog, discusses the history of ... needed to stop it. Yisrayl says mankind was created to ... experienced in today’s society. , “Yahweh created mankind, according ...
(Date:5/22/2015)... May 22, 2015 Pro3rd Impression ... designed exclusively for Final Cut Pro X. Pro3rd Impression's ... design. , Intuitive on-screen-controls allow users to customize ... Reflections, colors, layouts, and much more can be edited ... , Pro3rd Impression comes packed with 30 ...
Breaking Medicine News(10 mins):Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2
... shown that it seems to stop mice with the ... such vaccines could delay or prevent similar symptoms in ... deposits in mouse brains -the other major indicator of ... Ireland, is poised to begin human clinical trails of ...
... to test the importance of sleep for memory and ... effects, such as fatigue and reduced alertness. ... complications by allowing recovery sleep by Harvard Medical school ... day showed no improvement in task performance but those ...
... were 16 years old and the men were 13.5 years ... ,It appears that the sexual abuse or assault was ... thyroid diseases. It varied by gender, where arthritis and breast ... occur in men. ,There is an association between ...
... be remembered as one of the most controversial presidents ever. ... history to be impeached by the House of Representatives. Only ... save himself and his country further damage. ,He has ... and his mid east peace efforts have always come unstuck ...
... concluded Indian science congress in New Delhi have called for ... iron fortification of crops. Almost 50% of women and 75% ... While iron supplementation is expensive, fortification of plants with iron ... is fairly cheaper, scientists say. ,This idea has found ...
... scientists revealed that two antioxidants in black pepper and ... the bacterial DNA from damage by irradiation in test ... effect and protecting organisms like Escherichia role and Bacillus ... ,The study offers hope for the development of ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: